Skip to main content
Premium Trial:

Request an Annual Quote

PEOPLE: Hybrigenics New COO; BioProcessor Board Gets Millenium CTO; Orchid s New Director; and Others

NEW YORK, April 3 - Orchid BioSciences said today that it has added Kenneth Noonan to its board of directors.

 

Noonan replaces Anne VanLent, who resigned last year.

 

Noonan is a partner at London's LEK Consulting, where he leads the firm's life sciences practices in the United Kingdom and Europe.

 

Before that, he was senior vice president of corporate development for Applera, where he directed corporate alliance building and strategy for Celera Genomics and Applied Biosystems.

 

"Ken was an invaluable board member in Orchid's early days, and we are delighted to again have the benefit of his wealth of industry experience and insight," Orchid CEO Dale Pfost said in a statement.





Paris-based functional-proteomics company Hybrigenics said on Tuesday that it has hired Anne-Fabienne Weitsch as chief operating officer, a newly created position.

 

Weitsch, who will oversee management, business development, and drug discovery, was previously senior director of licensing and business development at Johnson & Johnson.

She has also worked in R&D at Zyma (now part of Novartis), and as a consultant in neurobiology and biochemistry at Geneva's Battelle Memorial Institut.

 


 

Mike Pavia, chief technology officer for Millennium Pharmaceuticals, has joined the board of microfluidics company BioProcessors.

 

BioProcessors, based in Woburn, Mass., is developing a microfluidic platform to allow for major parallel cell culture with the ability to simultaneously vary environmental parameters such as temperature, pH, and media conditions. The technology is designed to speed cell-based screening and pre-ADME evaluation.

 

The company was founded in October 2000.

 



Privately-held metabolomics company Lipomics Technologies said on March 29 that it had appointed Thomas Anderson as vice president for business development.

 

Anderson was co-founder, president, and chairman of Berkeley Antibody Company.

 

Lipomics, based in West Sacramento, Calif., specializes in quantitative lipid-metabolite analysis and metabolomic bioinformatic tools.

 


 

Promoted? Changing jobs? GenomeWeb wants to know. E-mail Kat McGowan at [email protected] to appear in PEOPLE, a roundup of personnel comings and goings in genomics that runs every Wednesday.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.